METABOLIC / FDA APPROVED
Retatrutide
Subcutaneous injection (weekly)
Overview
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization.
Mechanism of Action
This triple mechanism addresses obesity through complementary metabolic pathways.
​Research Summary & Key Findings
Phase 2 trial (2023) showed up to 24.2% body weight reduction at 48 weeks, the largest weight loss reported for any anti-obesity medication. Significant improvements in liver fat content observed in NAFLD sub-study. Phase 3 trials (TRIUMPH program) ongoing.
Clinical Status
FDA APPROVED
Retatrutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
Subcutaneous injection (weekly)
References
PRIMARY LITERATURE
PRIMARY LITERATUREPeer-reviewed literature indexed by the National Library of Medicine.
Registered interventional and observational studies, including status and phase.
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.